作者
Brent D. G. Page,Xiaolei Zhang,Jennifer M. Atkinson,Zhihua Li,Aaron D. Schimmer,Suzanne Trudel,James Turkson,Patrick T. Gunning
摘要
Abstract Stat3 is essential for transducing signals from extracellular stimuli, but also functions as a nuclear transcription factor required for regulating genes involved in proliferation, apoptosis, angiogenesis and invasion, in addition to genes encoding cytokines, chemokines and growth factors. In contrast to the transient nature of Stat3 activation in normal cells, many human cancers, including breast, prostate, ovarian, brain and multiple myeloma (MM) harbor constitutive Stat3 activity. Stat3 downstream target genes are critical to the dysregulated biological processes that promote tumor cell growth, survival and induce chemoresistance, thus targeting Stat3 signaling represents an important therapeutic target in cancer therapy. We have rationally designed and developed Stat3 inhibitors that disrupt transcriptionaly active Stat3-Stat3 homo-dimers, suppress Stat3 activation (phosphorylation), inhibit Stat3-target gene expression (c-Myc, Bcl-xL, survivin) and potently induce apoptosis in tumor cells harboring aberrant Stat3 activity. Moreover, lead compound BP-1–102, a salicylic acid containing small molecule, induced strong antitumor effects on human breast cancer (MDA-MB-231) xenografts and in MM preclinical tumor models. Most notably, given via oral gavage, BP-1–102 strongly inhibited the growth of human breast tumor xenografts, identifying it as a most potent orally bioavailable Stat3-targeting inhibitor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A125.